TGS COVID-19 IgG
Product Description
The TGS COVID-19 IgG test is a chemiluminescent two-step sandwich capture immunoassay (CLIA), for use on IDS-iSYS Multi-Discipline Automated System, for QUANTITATIVE determination of specific IgG class antibodies directed against the SARS-CoV-2 Spike and Nucleocapsid antigens in samples of human serum or plasma (K3-EDTA, sodium citrate, sodium heparin).
This assay is used as a diagnostic aid when assessing immunity status of patients related to COVID-19.
- Employs Spike (S1) and Nucleocapsid antigens for optimal detection, including no observed cross reactivity to other coronavirus strains
- QUANTITATIVE test for the assessment of IgG antibodies against SARS-CoV-2
- Excellent sensitivity and specificity
- Suitable for use with human serum or plasma
- Convenient reagents handling, with ready to use reagents combined with 60 days on-board storage
-
- Li, F., Li, W., Farzan, M., & Harrison, S. (2005). Structure of SARS coronavirus spike receptor-binding domain complexed with its 10.2210/pdb2ajf/pdb 3. Ou, X., Liu, Y., Lei, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun 11, 1620 (2020). View here
- Wu C, Liu Y, Yang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods [published online ahead of print, 2020 Feb 27]. Acta Pharm Sin B. 2020;10(5):766-788. doi:10.1016/j.apsb.2020.02.008
- Product Code: CVCL100G
- Number of Tests: 100
- Sample Type: Serum Plasma
- Sample Volume: 4 µL
- Assay Range: 0.0 – 160 AU/mL
- Add to Enquiry Basket
Interested? Enquire now.
Add to Enquiry Basket
Related Products
| Assays | Certification | Platform | Clinical Area | Portfolio | RUO/IVD |
|---|---|---|---|---|---|
| TGS COVID-19 IgM | CE Marked | i10iSYS | RespiratoryVaccine Preventable | Infectious Diseases | IVD |